Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Belite Bio, Inc

BLTE ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$154.74

▲ +2.97%

Market Cap $6.23B · Vol 73.48K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.23B

Mid Cap

Div Yield

N/A

EPS Growth

-27.14%

YoY

RSI (14)

46.27

Momentum

Beta

-1.26

vs Market

52W High

$200.00

22.63% below

52W Low

$98.30

57.42% above

Volume

73.48K

Avg 36.89K

P/B

8.17

Price-to-book

ROE

-16.94%

Return on equity

Free Float

56.03%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Belite Bio, Inc (BLTE) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BLTE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.03%

-8.88%

-3.24%

-2.78%

YTD

-3.26%

+57.74%

+312.53%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-77,611,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-16.94%
ROA · ROIC	-16.64% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	8.17
P/FCF	N/A
EPS Growth	-27.14%
Outstanding Shares	40.27M

Technical Indicators

50-Day SMA	$161.47
200-Day SMA	$160.36
RSI (14)	46.27
Beta	-1.26
52-Week High	$200.00
52-Week Low	$98.30

Volume Today	73.48K
Avg Daily Volume (30D)	36.89K
Relative Volume	1.99x
Volatility (10D)	38.04
Volatility (30D)	39.75
Free Float	56.03%

Analyst Consensus

BUY

Current Price $154.74

Mean Target $228.89

52W Low$98.30 52W High$200.00

Current

Target

$98.30 $200.00

Current Analyst target

+47.92% upside potential · 9 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG016LJYTW4

ISINUS07782B1044

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.